TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

INCLUSION CRITERIA:

   1. Signed & dated written informed consent obtained from subject in accordance w/local
   regulations.

   2. Histologically confirmed conventional and/or mucinous adenocarcinoma of the prostate.
   If histological confirmation is not available, cytological confirmation will be
   permitted in lieu.

   3. Must meet one of following 3 criteria for progressive disease following androgen
   deprivation:

A. Subjects w/nodal or visceral metastases:

Must have progressive disease defined by RECIST criteria or defined by the Prostate Cancer
Clinical Trials Working Group II (Scher et al. 2008).

B. Subjects w/no measurable disease:

PSA only disease must have an elevated PSA as defined by Consensus Criteria Prostate Cancer
Clinical Trials Working Group II (Scher et al. 2008). PSA must indicate progressive disease
defined as rising PSA values, at least 7 days apart, >2 ng/mL in the 28 days prior to
randomization.

C. Subjects w/bone involvement:

New disease on bone scan as defined by Consensus Criteria Prostate Cancer Clinical Trials
Working Group II (Scher et al. 2008). 4. Subjects on stable dose of bisphosphonates showing
subsequent tumor progression may continue on this medication; however, subjects are not
allowed to initiate bisphosphonate therapy w/in 28 days prior to starting study treatment
at Week 1 or at any time after that during the study, 5. Must be clinically
immunocompetent. Clinical immunocompetence assumed unless subject has been diagnosed as
immunosuppressed, is receiving immunosuppressive chemotherapy for oncology disorders, or is
receiving immunosuppressive therapy following transplant, in which case they will be
excluded.

6. Subject free of clinically apparent/active autoimmune disease (no prior confirmed
diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis,
Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, & Rheumatoid Arthritis).

7. Subject has adequate bone marrow function defined by Absolute Lymphocyte Count (ALC) ≥
500/µL, Absolute Neutrophil Count (ANC) >1200/µL, Platelet Count >100,000/µL.

8. Subject has peripheral neuropathy grade ≤1. 9. Subject has ECOG status of 0 or 1. 10.
Minimum life expectancy ≥6 months. 11. Progressive disease (as defined above) must be
documented after discontinuation of the hormonal and anti-androgen therapy.

12. Subject continues to stay on medical treatment such as LHRH agonists or LHRH
antagonists to maintain testosterone value of <50ng/dL.

EXCLUSION CRITERIA:

   1. Subject has received prior chemotherapy for prostate cancer at any time. Subject has
   received chemotherapy for any other reason within five years of screening.

   2. Subject is receiving any other hormonal therapy, including any dose of Megestrol
   Acetate, Finasteride, any herbal product known to decrease PSA levels (e.g., Saw
   Palmetto & PC-SPES), or any systemic corticosteroid must discontinue agent for at
   least 4 weeks prior to the anticipated Week 1 visit. LHRH agonists or LHRH antagonists
   do not need to be discontinued.

   3. Subject has started bisphosphonate or denosumab therapy less than 28 days before the
   anticipated Week 1 visit.

   4. Subject is using supplements or complementary medicines/botanicals. Subjects should
   review label w/their doctor prior to enrolment. Exceptions to this exclusion:

      - Conventional multivitamin supplements

      - Selenium

      - Lycopene

      - Soy supplements

      - Vitamin E

      - Fish oil supplements

      - Vitamin D

      - Glucosamine supplements

      - Age-related eye disease vitamins

      - Ginkgo biloba

   5. Subject has had major surgery or radiation therapy completed <4 weeks prior to
   screening.

   6. Corticosteroids are not permitted except for (a) nasal sprays and inhalers, (b) orally
   prescribed as replacement therapy in the case of adrenal insufficiency, (c) oral or IV
   dexamethasone administration used acutely in combination with docetaxel, (d)
   parenteral use on a single occasion, (e) low dose parenteral use for a maximum of 5
   days and (f) acute and sporadic parenteral use for acute asthma.

   7. Subject is known to test positive for HIV or hepatitis B or C.

   8. Subject receiving concurrent chemotherapy, immunotherapy, radiotherapy or
   investigational agents.

   9. Subject has Platelet count >400,000/μL; Monocytes >80,000/μL; Haemoglobin <11g/dL.

10. Subject has cerebral metastases (known from previous investigations or clinically
   detectable).

11. Subject has serum testosterone >50ng/dL.

12. Subject has rheumatoid disease (asymptomatic subjects w/controlled & rarely flaring
   rheumatoid arthritis are also excluded).

13. Subject exhibits evidence of symptomatic congestive heart failure, pulmonary embolus,
   vascular thrombosis, transient ischemic attack, cerebrovascular accident, unstable
   angina, myocardial infarction or active ischemia on ECG. If an ECG taken prior to
   screening but within 28 days of the anticipated Week 1 visit is not available, an ECG
   must be performed at screening.

14. Subject has uncontrolled severe hypertension >150/100mm Hg (if controlled w/medication
   this is not an exclusion).

15. Subject is hypotensive.